Longevity Acquisition Corporation Announces Results of Special Meeting of Shareholders
NEW YORK, March 18, 2021 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today the results of its special meeting of shareholders, which was held onMarch 17, 2021. At the special meeting, sharehold...
Longevity Acquisition Corporation Announces 4D pharma Clinical Trial Collaboration and Supply Agreement for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that onFebruary 8, 2021, 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of Liv...
Longevity Acquisition Corporation Announces 4D pharma Update on Oncology Program
NEW YORK, Feb. 3, 2021 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that onFebruary 3, 2021, 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of Liv...
Longevity Acquisition Corporation Announces 4D pharma Joining Landmark Parkinson's Progression Markers Initiative
NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that onDecember 18, 2020, 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of L...
Longevity Acquisition Corporation Regains Compliance with Nasdaq Listing Requirement
NEW YORK, Dec. 11, 2020 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that onDecember 10, 2020, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock M...
Longevity Acquisition Corporation Announces Extension of Deadline to Complete a Business Combination
NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that it has elected to extend the date by which it has to consummate a business combination fromNovember 30, 2020 to M...
Longevity Acquisition Corporation Announces Increased Cash Contribution for the Extension
NEW YORK, Nov. 17, 2020 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company" or "LOAC"), a publicly-traded special purpose acquisition company (SPAC), announced that in light of the upcoming special shareholder meeting (the "Special Meeting"), if the shareholders approv...
Longevity Acquisition Corporation Announces Signing of Definitive Merger Agreement
SHANGHAI, Oct. 22, 2020 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company" or "LOAC"), a publicly-traded special purpose acquisition company (SPAC), announced that it has signed a definitive merger agreement with 4D pharma PLC (AIM: DDDD, "4D pharma" or "4D"). Upon co...
Longevity Acquisition Corporation Announces Extension of Deadline to Complete a Business Combination
NEW YORK, May 22, 2020 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that it has elected to extend the date by which it has to consummate a business combination fromMay 29, 2020 to November ...
